NYMOX Provides Current Update
13 sept. 2022 09h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with...
NYMOX Updates Shareholders
15 juil. 2022 09h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities....
NYMOX Receives Deficiency Letter from NASDAQ
14 juil. 2022 12h18 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the...
NYMOX Receives RTF letter from FDA
23 mai 2022 08h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at...
Nymox Announces Closing of $6.4 Million Financing
04 avr. 2022 09h45 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in...
Nymox Announces $5 Million Registered Direct Offering
18 mars 2022 08h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited...
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
03 mars 2022 11h00 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug...
Nymox Shareholder Update
13 déc. 2021 09h30 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has completed all the Company’s required...
NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference
15 nov. 2021 11h39 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today that it will be presenting at the Torrey Hills...
NYMOX Provides Current Update
11 oct. 2021 10h30 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as a...